Tumor-Selective Radiopharmaceutical Targeting via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 1003-1008

  Mathias, Carla J ^a   Wang, Susan ^a   Lee, Robert J ^a   Waters, David J ^a   Low, Philip S ^a   Green, Mark A ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Folate binding protein; Gallium 67; Receptor mediated endocytosis; Tumor imaging

Indexed keywords

CARRIER PROTEIN; CELL SURFACE RECEPTOR; DEFEROXAMINE; DEFEROXAMINE GAMMA FOLATE CONJUGATE; DEFEROXAMINE-GAMMA-FOLATE CONJUGATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FOLATE BINDING PROTEIN; FOLATE-BINDING PROTEIN; FOLIC ACID;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; ENDOCYTOSIS; EXPERIMENTAL NEOPLASM; MALE; METABOLISM; MOUSE; NASOPHARYNX TUMOR; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; CARRIER PROTEINS; DEFEROXAMINE; ENDOCYTOSIS; FOLIC ACID; MALE; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0030163022     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Anderson RGW, Kamen BA, Rothberg KG, et al. Potocytosis: sequestration and transport of small molecules by caveolae. Science 1992;255:410-411.
2. Forgac M. Structure and function of vacuolar class of ATP-driven pumps. Physiological Rev 1989;69:765-795.
3. Darnell JE, Molecular Cell Biology. San Francisco: W.H. Freeman; 1990:555-561.
4. Anderson RGW. The link between clathrin-coated pits and receptor mediated endocytosis. In: (Lonsdale-Eccles JD, ed.) Protein traffic in parasites and mammalian cells: proceedings of a workshop held at the International Laboratory for Research on Animal Diseases. Nairobi, Kenya: Majestic Printing Works; 1989:18-21.
5. Pastan I, Willingham MC. The pathway of endocytosis. In: Pastan I, Willingham MC, eds. Endocytosis. New York: Plenum Press; 1985:1-40.
6. Leamon CP, Low PS. Delivery of macromoleculcs into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 1991;88:5572-5576.
7. Leamon CP, Low PS. Cytotoxicity of momordin-folate conjugates in cultured human cells. J Biol Chem 1992;267:24966-24971.
8. Leamon CP, Low PS. Membrane folate binding proteins are responsible for the folate-protein conjugate endocytosis into cultured cells. Biochem J 1993;291:855-860.
9. Leamon CP, Pastan I, Low PS. Cytotoxicity of folate-Pseudomonas exotoxin conjugates towards tumor cells: contribution of translocation domain. J Biol Chem 1993;268:24847-24854.
10. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor- mediated endocytosis. J Biol Chem 1994;269:3198-3204.
11. Leamon CP, Low PS. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Targeting 1994;2:101-112.
12. Turek JJ, Leamon CP, Low PS. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J Cell Sci 1993;106:423-430.
13. Antony AC, Kane MA, Portillo RM, et al. Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J Biol Chem 1985;260:14911-14917.
14. Henderson GB, Tsuji JM, Kumar HP. Mediated uptake of folate by a high-affinity binding protein in sublines of L1210 cells adapted to nanomolar concentrations of folate. J Membrane Biol 1988;101:247-258.
15. Pizzorno G, Cashmore AR, Moroson BA, et al. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. J Biol Chem 1993;268: 1017-1023.
16. Sirotnak FM. Obligate genetic expression in tumor cells of a fetal membrane property mediating folate transport: biological significance and implications for improved therapy of human cancer. Cancer Res 1985;45:3992-4000.
17. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-3401.
18. Miotti S, Canevari S, Menard S, et al. Characterization of human ovarian carcinoma- associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987;39:297-303.
19. Mezzanzanica D, Garrido MA, Neblock DS, et al. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model. Cancer Res 1991;51:5716-5721.
20. Rothenberg SP, DaCosta M. Further observations on the folate-binding factor in some leukemic cells. J Clin Invest 1971;50:719-726.
21. Westerhof GR, Jansen G, van Emmerik N, et al. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res 1991;51:5507-5513.
22. Coney LR, Tomasetti A, Carayannopoulos I, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991;51:6125-6132.
23. Campbell IG, Jones TA, Foulkes WD, et al. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991;51:5329-5338.
24. Franklin WA, Waintrub M, Edwards D, et al. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer 1994;8: 89-95.
25. Mantovani LT, Miotti S, Menard S, et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies Mov18 and Mov19. Eur J Cancer 1994:30A:363-369.
26. Holm J, Hansen SI, Sondergaard K, Hoier-Madsen M. The high affinity folate binding protein in normal and malignant mammary gland tissue. Chem Biol Pteridines and Folates 1993:757-760.
27. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissue in vivo and in established cell lines. Cancer 1994;73:2432-2443.
28. Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer antigen LK26: Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142:557-567.
29. 67Ga-deferoxamine- folate conjugate. Bioconj Chem: in press.
30. Bates RG, Vega CA, White DR. Standards for pH measurements in isotonic saline media of ionic strength 1 = 0.16. Anal Chem 1978;50:1295-1300.
31. McHugh M, Chang YC. Demonstration of a high affinity folate binder in human cell membrane and its characterization in cultured human KB cells. J Biol Chem 1979;254:11312-11318.
32. Kutsky RJ. Handbook of vitamins, minerals and hormones, 2nd ed. New York, NY: Van Nostrand Reinhold; 1981:273.
33. Samuels ML. Statistics for the life sciences. San Francisco, CA: Dellen Publishing; 1989:249-256.
34. Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. N Eng J Med 1976;294:1421-1423.
35. Weiner RE, Thakur ML, Goodman M, Hoffer PB. Relative stability of In-111 and Ga-67 desferrioxamine and human transferrin complexes. Radiopharmaceuticals II. New York, NY: Society of Nuclear Medicine: 1979:331-340.
36. Yokoyama A, Ohmomo Y, Horiuchi K, et al. Deferoxamine, a promising bifunctional chelating agent for labeling proteins with gallium: Ga-67 DF-HSA. J Nucl Med 1982;23:909-914.
37. Janoki AG, Harwig JF, Wolf W. Studies on high specific activity labeling of proteins using bifunctional chelates: Ga-67-DF-HSA. Nucl Med Biol 1982;1:689-692.
38. 67Ga-labeled antibodies using desferrioxamine as a bifunctional chelate, an improved method. J Immunol Meth 1987;104:93-102.
39. Vera DR. Gallium-labeled deferoxamine-galactosyl-neoglycoalbumin: a radiopharmaceutical for measurement of hepatic receptor biochemistry. J Nucl Med 1992;33:1160- 1166.
40. Smith-Jones PM, Stoltz B, Bruns C, et al. Gallium-67/gallium-68-[DFO]-octreotide- a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317-325.
41. Harris WR, Pecoraro VL. Thermodynamic binding constants for gallium transferrin. Biochemistry 1983;22:292-299.
42. Larson SM. Mechanisms of localization of gallium-67 in tumors. Sem Nucl Med 1978;3:193-204.
43. Hoffer P. Gallium: mechanisms. J Nucl Med 1980;21:282-285.
44. Green MA, Welch MJ. Gallium radiopharmaceutical chemistry. Nucl Med Biol 1989;16:435-448.